SEC Form 4 · accession 0000880771-16-000185
SCICLONE PHARMACEUTICALS INC · SCLN
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Friedhelm Blobel
Officer — President & CEO · Director
Period of report
Aug 12, 2016
Accepted (ET)
Aug 16, 2016 · 5:41 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000880771
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Aug 12, 2016 | M | 3,500 | $0.00 | A | 463,782 | D | |
| Common Stock | Aug 12, 2016 | M | 5,000 | $0.00 | A | 468,782 | D | |
| Common Stock | Aug 12, 2016 | M | 50,000 | $0.00 | A | 518,782 | D | |
| Common Stock | Aug 12, 2016 | F | 1,827 | $10.41 | D | 516,955 | D | |
| Common Stock | Aug 12, 2016 | F | 26,090 | $10.41 | D | 490,865 | D | |
| Common Stock | Aug 12, 2016 | F | 2,610 | $10.41 | D | 488,255 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Restricted Stock UnitF3,F4,F5 | — | Aug 12, 2016 | A | 40,000 | A | — | — | Common Stock | 40,000 | 383,500 | D |
| Restricted Stock UnitF6,F4,F7 | — | Aug 12, 2016 | M | 3,500 | D | — | — | Common Stock | 3,500 | 380,000 | D |
| Restricted Stock UnitF6,F4,F8 | — | Aug 12, 2016 | M | 5,000 | D | — | — | Common Stock | 5,000 | 375,000 | D |
| Restricted Stock UnitF6,F4,F9 | — | Aug 12, 2016 | M | 50,000 | D | — | — | Common Stock | 50,000 | 325,000 | D |
Explanation of responses
- F1Includes 1,000 shares purchased under the Issuer's Employee Stock Purchase Plan on May 31, 2016.
- F2Shares disposed represent shares withheld to cover withholding tax obligations in connection with the vesting of Restricted Stock Units.
- F3Granted under the Issuer's 2015 Equity Incentive Plan.
- F4Each restricted stock unit represents the contingent right to receive one share of SciClone Pharmaceuticals, Inc.'s common stock.
- F5Each RSU will vest and be settled on August 15, 2017, subject to the reporting person's continued employment, but will terminate upon the occurrence of a change in control on or before March 31, 2017.
- F6Granted under the Issuer's 2005 Equity Incentive Plan.
- F7Vesting for such RSUs will occur 50% on February 20, 2015 and 50% on February 20, 2016, or on such later date thereafter as the Company's trading window opens if it is not open on either of such dates.
- F8Vesting for such RSUs will occur 25% on March 16, 2016, 25% on March 16, 2017, 25% on March 16, 2018, and 25% on March 16, 2019, or on such later date thereafter as the Company's trading window opens, if it is not open on any of such dates, contingent upon the executive's continued employment.
- F9Vesting to be in three equal annual installments at the close of business on the first business day following December 31 of each of calendar year 2015, 2016, and 2017, provided that the Participant's service with the Company has not terminated prior to the applicable vesting time.